| 晨会聚焦 | | --- | | 一、财信研究观点 | | 【市场策略】大盘放量上涨，资源股持续发酵 | | 【基金研究】基金数据日跟踪 | | 【债券研究】债券市场综述 | | 二、重要财经资讯 | | 【宏观经济】香港财政司发表 2026 至 2027 财政年度政府财政预算案 | | 【宏观经济】美国总统特朗普在国会发表其第二任期的首次国情咨文演 | | 讲 | | 【宏观经济】央行开展 亿元 操作 6000 MLF | | 【财经要闻】2026 中关村论坛年会将于 3 月 25 日至 29 日在京举办 | | 【财经要闻】2026 年 月月末全国乘用车行业库存 万辆 1 357 | | 三、行业及公司动态 | | 【行业动态】上海五部门：非沪籍外环内购房社保年限降至 1 年，缴满 3 | | 年可增购 1 套 | | 【公司跟踪】复星医药（600196.SH）：芦沃美替尼片的临床试验申请获 | | 得批准 | | 【公司跟踪】影石创新（688775.SH）发布 年业绩快报：归母净利 2025 | | 润同比-3.08% | | 【公司跟踪】苏泊尔（002032.SZ）发布 2025 年业绩快报：归母 ...

根据公告，芦沃美替尼片为MEK1/2选择性抑制剂。目前，该药品已于中国境内（不含港、澳、台地 区）上市并获批两项适应症，包括用于治疗朗格汉斯细胞组织细胞增生症（LCH）和组织细胞肿瘤成人 患者以及2岁及2岁以上伴有症状、无法手术的丛状神经纤维瘤（PN）的Ⅰ型神经纤维瘤病（NF1）儿 童及青少年患者。 北京商报讯（记者 王寅浩 宋雨盈）2月25日，复星医药发布公告称，公司控股子公司上海复星医药产业 发展有限公司收到国家药品监督管理局关于同意复迈宁®（通用名：芦沃美替尼片）联合安罗替尼用于 鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌（NSCLC）患者开展临床试验的批准。复星医 药产业拟于条件具备后开展该药品的Ⅱ期临床试验。 ...

截至2026年1月，本集团现阶段针对该药品的累计研发投入约为人民币6.68 亿元(未经审计)。 根据IQVIA MIDAS™最新数据，2024年，MEK1/2选择性抑制剂于全球范围的销售额约为20.68亿美 元。 该药品为本集团(即本公司及控股子公司/单位，下同)自主研发的创新型小分子化学药物，为MEK1/2选 择性抑制剂。 截至本公告日期(即2026年2月25日)，该药品的其他注册或临床进展如下： 1、该药品已于中国境内上市 并获批两项适应症，包括用于治疗朗格汉斯细胞组织细胞增生症(LCH)和组织细胞肿瘤成人患者;2岁及2 岁以上伴有症状、无法手术的丛状神经纤维瘤(PN)的Ⅰ型神经纤维瘤病(NF1)儿童及青少年患者。 2、 该药品另有两项适应症的药品上市申请已获国家药监局受理并获纳入优先审评程序，包括用于治疗2岁 及2岁以上朗格汉斯细胞组织细胞增生症(LCH)儿童患者;用于治疗伴有症状、无法手术的丛状神经纤维 瘤(PN)的Ⅰ型神经纤维瘤病(NF1)成人患者。3、该药品用于治疗儿童低级别脑胶质瘤于中国境内处于Ⅲ 期临床试验阶段、用于治疗颅外动静脉畸形于中国境内处于Ⅱ期临床试验阶段。 智通财经APP讯，复星医药 ...

该药品为本集团（即本公司及控股子公司/单位，下同）自主研发的创新型小分子化学药物，为MEK1/2 选择性抑制剂。 格隆汇2月25日丨复星医药(600196.SH)公布，公司控股子公司上海复星医药产业发展有限公司（以下简 称"复星医药产业"）收到国家药品监督管理局关于同意复迈宁®（通用名：芦沃美替尼片；以下简 称"该药品"）联合安罗替尼用于鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌（NSCLC）患 者（以下简称"本次新增适应症"）开展临床试验的批准。复星医药产业拟于条件具备后于中国境内1开 展该药品的Ⅱ期临床试验。 ...

Core Viewpoint - Fosun Pharma's subsidiary has received acceptance for the marketing application of Luwo Meitin tablets, a treatment for symptomatic, inoperable plexiform neurofibromas in adult patients with type I neurofibromatosis, which is now included in the priority review process by the National Medical Products Administration [1] Group 1 - The drug Luwo Meitin (generic name: Luwo Meitin tablets) is a selective inhibitor of MEK1/2 [1] - The drug has already been approved for two indications in mainland China (excluding Hong Kong, Macau, and Taiwan) [1] - The approved indications include treatment for adult patients with Langerhans cell histiocytosis and tissue tumors, as well as for children and adolescents aged 2 years and older with symptomatic, inoperable plexiform neurofibromas [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., has received acceptance for the drug application of Fumainin® (generic name: Luwomeitini tablets) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with Neurofibromatosis type 1 (NF1), which has been included in the priority review process by the National Medical Products Administration [1] Group 1 - The drug Fumainin® is developed for a new indication targeting adult patients with NF1 [1] - The application for the drug has been accepted by the National Medical Products Administration [1] - The drug has been included in the priority review process, indicating its potential significance in the market [1]

该药品为本集团（即本公司及控股子公司/单位，下同）自主研发的创新型小分子化学药物，为MEK1/2 选择性抑制剂。 格隆汇2月5日丨复星医药(600196.SH)公布，公司控股子公司上海复星医药产业发展有限公司（称"复星 医药产业"）自主研发的复迈宁®（通用名：芦沃美替尼片；称"该药品"）用于治疗伴有症状、无法手 术的丛状神经纤维瘤（PN）的Ⅰ型神经纤维瘤病（NF1）成人患者（称"新增适应症"）的药品上市申请 获国家药品监督管理局受理并已获纳入优先审评程序。 ...

Core Insights - In 2025, China's innovative pharmaceutical industry reached a "golden moment" with 76 innovative drugs approved, over 80% of which were domestically developed, and total licensing transaction amounts exceeding $130 billion, marking a historical high [2][5] - The surge in innovative drugs reflects a significant shift from quantity to quality, with over one-third of the approved drugs targeting cancer treatment, and a notable presence of GLP-1 drugs for metabolic diseases [3][4] - The capital market responded positively, with the Hong Kong innovation drug index rising by 66.52%, outperforming the Hang Seng Index, indicating strong market confidence in the sector [9] Group 1: Innovative Drug Approvals - A total of 76 innovative drugs were approved in 2025, significantly higher than the 48 approved in 2024, including 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [2] - Among the approved chemical drugs, 80.85% were domestically developed, while 91.30% of biological products were also from domestic sources, showcasing the dominance of local innovation [2] Group 2: Market Trends and Drug Development - The oncology sector led the innovation with over 20 drugs, accounting for approximately one-third of the total, while metabolic diseases represented about 20% of the approvals, highlighting the diverse therapeutic areas being addressed [3] - The approval of first-in-class drugs in China, with 4 out of 11 being domestically developed, signifies a shift towards more innovative and effective treatments available to patients [4] Group 3: Licensing and International Collaboration - The total value of licensing transactions for Chinese innovative drugs surpassed $130 billion in 2025, with over 150 deals, reflecting a significant increase compared to 2024 [5][6] - Notable collaborations included a $10.8 billion deal between Innovent Biologics and Roche, and a $12.5 billion upfront payment from Pfizer to 3SBio, indicating a trend towards deeper strategic partnerships [5][6] Group 4: Capital Market Performance - The performance of the innovative drug sector in the capital market was robust, with the Hong Kong innovation drug index increasing by 66.52%, and the CS innovation drug index in A-shares rising by 19.34% [9] - The successful commercialization of leading biotech companies like BeiGene and Innovent Biologics demonstrates the growing profitability and market presence of Chinese innovative drug firms [9] Group 5: Future Outlook - The ongoing reforms in drug approval processes and supportive policies are expected to further enhance the development of innovative drugs in China, positioning the country as a key player in global pharmaceutical innovation [8][10] - Predictions indicate that the next five years will see an increase in the proportion of original innovative drugs, with a focus on balancing scientific exploration and commercial value [11][12]

Core Insights - The total transaction amount for new drug licensing has exceeded $130 billion, with the number of transactions surpassing 150, both reaching historical highs [1] - A total of 76 new drugs were approved for market launch, significantly exceeding the 48 approved in 2024, marking a historical peak [1] Industry Growth - The approval of first-class new drugs in China has increased significantly from 2018 to 2024, with 48 approved in 2024, over five times the number in 2018 [3] - Domestic drugs accounted for over 85% of the 76 new drugs approved in 2025, indicating a shift towards domestic innovation [3] - Among the newly approved drugs, 11 are globally innovative, with 4 developed independently in China, showcasing substantial progress in original innovation capabilities [3] Patient Impact - The acceleration of new drug innovation means more patients will receive effective treatments, enhancing public health security [4] - The approval of innovative drugs during the 14th Five-Year Plan period is expected to reach around 220, addressing major diseases and improving patient outcomes [4] Corporate Development - Jiangsu Hengrui Medicine exemplifies the success of increased investment in new drug innovation, with R&D expenditure rising from approximately 19% of revenue in 2015 to about 30% in 2024 [5] - The company has developed 24 first-class new drugs and 5 second-class new drugs, maintaining a position among the top 50 global pharmaceutical companies for seven consecutive years [5] - The large patient population in China allows companies to quickly realize substantial returns on successful drug development [5] Regulatory Environment - The reform of drug review and approval systems has significantly shortened the average review time from 14 months to 30 days, enhancing the efficiency of new drug approvals [6] - The Chinese government has implemented various supportive policies to foster new drug innovation, contributing to the rapid development of the pharmaceutical industry [6] - The ongoing reforms and supportive measures are expected to usher in a golden era for new drug innovation in China [6]

Core Insights - The new National Medical Insurance Drug List and Commercial Health Insurance Innovative Drug List will be implemented in Wuhan starting January 1, 2026, focusing on "clinical urgency, affordability, and diverse coverage" [1] - The updated list includes 114 new drugs, with a significant emphasis on oncology and rare diseases, complementing the basic medical insurance coverage [2][5] Summary by Sections New Drug Inclusion - The revised National Medical Insurance Drug List now includes a total of 3,253 drugs, with 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - Among the 114 newly added drugs, 50 are classified as innovative drugs, achieving a high inclusion success rate of 88%, with over 90% being newly approved in the last five years [2] Price Reductions - The average price reduction for the newly included drugs is 63%, with some high-profile drugs seeing reductions exceeding 70% [3] - For instance, the monthly cost of the drug Tirzepatide, previously between 1,700 to 2,000 yuan, is now reduced to 324.1 yuan for the 2.5 mg dosage and 936.7 yuan for the 10 mg dosage, significantly lowering the annual burden for patients in Wuhan by over 15,000 yuan [3] Commercial Health Insurance Innovations - The first edition of the Commercial Health Insurance Innovative Drug List includes 19 high-value innovative drugs, addressing gaps in basic medical insurance coverage [5] - This list features CAR-T cell therapy drugs and treatments for rare diseases, with some therapies costing over 400,000 yuan annually [5] Dual-Channel System Expansion - The dual-channel drug list has expanded to 621 drugs, significantly increasing from the previous version [7] - This includes 321 drugs for targeted therapies, rare diseases, infectious diseases, and mental health, with specific policies for outpatient special diseases to ensure precise benefit delivery [7] Streamlined Processes - All designated retail pharmacies in Wuhan have implemented electronic prescription systems, allowing patients to choose between hospital pharmacies and designated stores for immediate reimbursement [7] - The new system aims to enhance efficiency and reduce patient wait times, promoting a more convenient healthcare experience [7] Collaboration and Communication - Wuhan is establishing a continuous communication platform between pharmaceutical companies and medical institutions to facilitate the understanding of new drug characteristics and supply [8] - By February 2026, all medical institutions are required to adjust their drug procurement processes to ensure the availability of newly negotiated drugs [8]